TP53 and acute myeloid leukemia: In order to test whether the mevalonate and/or Wnt pathways, prominent members of which we found to be differentially expressed in a TP53-dependent manner, are involved in determining the efficacy of CAR T-cell-mediated killing of TP53-deficient AML cells, we sought to target these pathways pharmacologically in co-culture killing assays in vitro (Fig. 5A).